Document Detail


Management of uterine hyperstimulation after prostaglandin E2 administration.
MedLine Citation:
PMID:  3476877     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent literature suggests that intravaginal or intracervical application of prostaglandin E2 gel may be an effective agent for cervical ripening. One potentially disastrous reported side effect is uterine hyperstimulation. This case report represents the first description of the successful management of uterine hyperstimulation with intravenous ritodrine therapy after the intravaginal administration of prostaglandin E2.
Authors:
G L Goyert; F G Mariona
Related Documents :
1154017 - An investigation into the use of anafranil in phobic and obsessional disorders.
19917737 - The effect of heel height on gait and posture: a review of the literature.
2644317 - Cutaneous effects and therapeutic uses of heat with emphasis on infrared radiation.
3476877 - Management of uterine hyperstimulation after prostaglandin e2 administration.
11862167 - Early-onset of septo-optic dysplasia. a case report with follow-up.
21052957 - Do erythropoietic-stimulating agents relieve fatigue? a review of reviews.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  70     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1987-09-25     Completed Date:  1987-09-25     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  468-70     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravaginal
Adult
Dinoprostone
Female
Heart Rate, Fetal / drug effects
Humans
Labor, Induced
Medication Errors
Pregnancy
Prostaglandins E / administration & dosage,  adverse effects*
Ritodrine / therapeutic use*
Uterine Contraction / drug effects*
Chemical
Reg. No./Substance:
0/Prostaglandins E; 26652-09-5/Ritodrine; 363-24-6/Dinoprostone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  McArdle's disease in two generations: autosomal recessive transmission with manifesting heterozygote...
Next Document:  Retained alloplastic temporomandibular joint disk implants: a retrospective study.